Clinical trials: Influenza Virus
Influenza
A Study of the Safety, Tolerability & Immunogenicity of CSL Limited's Influenza Virus Vaccine In a Paediatric Population
The purpose of this study is to determine the Safety, Tolerability \& Immunogenicity of CSL Limited's Influenza Virus Vaccine in a two dose primary vaccination series, with a 12-month booster vaccination, in a paediatric…
- Trial name
- NCT00700193
- Testing
- Influenza Virus Vaccine
- Where
- Australia
- Volunteers
- 298 people, healthy volunteers welcome
- Sponsor
- Seqirus
Respiratory Tract Infections, Influenza, Human
Idylla IFV-RSV Panel Clinical Testing
This clinical study will collect fresh samples and perform laboratory testing on fresh and archived samples as described in the protocol.
- Conditions
- Respiratory Tract Infections, Influenza, Human, Respiratory Syncytial Virus Infections
- Trial name
- RP1 (NCT02786381)
- Where
- United States
- Volunteers
- 213 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Severe Influenza
Evaluate the Safety and Efficacy of Xiyanping in Pediatric Participants With Severe Influenza-Like Symptoms
This is a multicenter, randomized, open Label, add-on study.
- Trial name
- NCT03947411
- Testing
- Oseltamivir Phosphate, Xiyanping injection+Oseltamivir Phosphate
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Influenza
Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above
Today, the leading contender for the next pandemic of influenza is H5N1, a strain of avian virus. Prevention and control will depend on the rapid production and worldwide distribution of specific pandemic vaccines.
- Trial name
- NCT00319098
- Testing
- Adjuvanted pandemic influenza candidate vaccine, Fluarix
- Where
- 40 sites in Estonia, France and 5 more
- Volunteers
- 5,075 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Dose-escalation Study of Single Dose GHB04L1 in Healthy Adults
It is the hypothesis of this study that intranasal vaccination with a single dose of GHB04L1 is safe and induces an immune response against influenza A H5N1.
- Trial name
- GHB-CS03 (NCT00741806)
- Testing
- GHB04L1
- Where
- Austria
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AVIR Green Hills Biotechnology AG
Influenza
Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model
This will be a randomized, double-blind, placebo-controlled proof of concept study to evaluate the prophylactic efficacy and safety of orally administered TRX-100 in healthy adults challenged with influenza A/France/759/2021…
- Trial name
- NCT07503405
- Testing
- TRX-100, Influenza A/France/759/2021 (H1N1) virus
- Where
- United Kingdom
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Traws Pharma, Inc.
Influenza
Intracutaneous Delivery of Varied Dose Volumes of Saline
This study will evaluate intracutaneous delivery of 0.1, 0.25 and 0.5 milliliter volumes of saline from the FLUGEN 101.2 investigational microneedle-based device.
- Trial name
- NCT01767337
- Testing
- FLUGEN 101.2 device
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- FluGen Inc
Influenza
Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup
The study primarily aims to evaluate immunogenicity and safety of influenza vaccines (cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free…
- Trial name
- NCT00579345
- Testing
- Cell culture derived seasonal trivalent influenza vaccine (cTIV), Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a)., cTIV or eTIV_a
- Where
- 5 sites in Poland
- Volunteers
- 1,522 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza
Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2010/2011 Season
Influenza (flu) viruses change continuously, therefore also the parts of viruses used in influenza vaccines can vary from year to year.
- Trial name
- NCT01146015
- Testing
- Trivalent influenza subunit vaccine Influvac
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Abbott Biologicals
Influenza
Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Children
A single center, stratified, randomized and double-blind phase II clinical trial was conducted in children to evaluate the safety and immunogenicity of an split-virion pandemic influenza A vaccine (H5N1).
- Trial name
- NCT00900991
- Testing
- split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza
Influenza Burden Assessment in the United States, July1997 - up to April 2009
The study will assess the burden of severe influenza outcomes by age, risk status, and influenza subtype, in order to create a profile of the burden of influenza-related morbidity and mortality in United States from July 1997 to…
- Trial name
- NCT01599390
- Testing
- Data collection
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Observation Safety
Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age
This is an observational post-marketing study conducted in children and adults immunized with Q/LAIV as part of routine clinical practice at Kaiser Permanente Northern California (NCKP) sites.
- Trial name
- NCT01985997
- Where
- United States
- Volunteers
- 95,000 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Pregnancy, Influenza
Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry
The Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry will be a prospectively recruited pregnancy surveillance program designed to collect and analyze information on vaccine exposures, pregnancy outcomes, and…
- Trial name
- NCT01945424
- Testing
- Quadrivalent Influenza Vaccine (QIV)
- Where
- 5 sites in United States
- Volunteers
- 244 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Human Influenza
A Study to Evaluate Safety and Immunogenicity of Trivalent Influenza Vaccine, Formulation 2015 Southern Hemisphere, When Administered to Healthy Adult Subjects.
The present study is designed to evaluate the safety and immunogenicity of trivalent, surface antigen, inactivated influenza vaccine in 2 age cohorts: 18 to ≤60 years and ≥61 years.
- Trial name
- NCT02427750
- Testing
- Aggripal®
- Where
- Brazil
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza and Acute Respiratory Viral Infections
Efficacy of Anaferon for Children in the Treatment of Influenza and Acute Respiratory Viral Infections in Children
The purpose of this study is: To obtain additional data on therapeutic efficacy of Anaferon for children in the treatment of influenza and acute respiratory viral infections in children
- Trial name
- NCT02072174
- Testing
- Anaferon for Children
- Where
- 27 sites in Belarus, Russia and 1 more
- Volunteers
- 569 people
- Sponsor
- Materia Medica Holding
Influenza
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
The purpose of this study is to evaluate the immunogenicity and the safety of GlaxoSmithKline (GSK) Biologicals' investigational quadrivalent split virion influenza vaccine FLU-Q-QIV in adults 18 years of age and older.
- Trial name
- NCT01440387
- Testing
- FLULAVAL® QUADRIVALENT
- Where
- Canada
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Virus Diseases, RNA Virus Infections
Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults
A phase II trial multicenter, observer-blind, randomized, dose-ranging, placebo-controlled study to evaluate the immunogenicity, safety, and tolerability of a single intramuscular injection of plant-derived Seasonal VLP…
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT02233816
- Testing
- Low dose of quadrivalent VLP vaccine, Medium dose of quadrivalent VLP vaccine, High dose of quadrivalent VLP vaccine
- Where
- 2 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Medicago
Influenza
Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India
The aim of the study was to generate immunogenicity and safety data in the whole population to support registration of the Quadrivalent Influenza Vaccine (QIV) in India: Primary objective: To describe in each age group the immune…
- Trial name
- NCT02451358
- Testing
- Quadrivalent Inactivated Influenza Vaccine (2016-2017 NH formulation), No Preservative, Quadrivalent Inactivated Influenza Vaccine (2016 SH formulation), No Preservative, Quadrivalent Inactivated Influenza Vaccine (2015-2016 NH formulation), No Preservative
- Where
- 8 sites in India
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Safety, Tolerability and Pharmacokinetic Study of Biota-CS-8958
This study will look at the safety, tolerability and what the body does to CS-8958 given to 40 healthy volunteers 18-55 years old.
- Trial name
- NCT00311714
- Testing
- CS-8958 formulated as dry powder
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Biota Scientific Management Pty Ltd
Respiratory Syncytial Virus Infections
A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.
The purpose of this study is to evaluate the clinical lot-to-lot consistency of the respiratory syncytial virus (RSV) maternal (RSV MAT) vaccine administered to healthy non-pregnant women 18-49 years of age (YOA).
- Trial name
- NCT05045144
- Testing
- RSVPreF3(120 μg), Flu Quadrivalent influenza vaccine (15 μg HA)
- Where
- 36 sites in United States, Canada and 3 more
- Volunteers
- 1,586 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.